ClinicalTrials.gg
CompletedNCT06979687Updated May 29, 2025

Knotless Barbed Suture Closure of the Uterus at Caesarean Section

An observational study in Caesarean Section and Caesarean Section; Infection, sponsored by South Tees Hospitals NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to female participants. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by South Tees Hospitals NHS Foundation Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
957
Sex
Female
01

Study summary

Caesarean section (CS) is an increasingly common mode of delivery. The way in which this operation is carried out is important as it affects millions of women each. In recent years use of a 'self-retaining' suture or thread for closure of the uterine closure has become a recognised approach with a proven safety record. These sutures are known as knotless barbed sutures (KBS) as the unidirectional barbs on the surface of the suture hold the suture in the tissue without the need for knots. These sutures can be used instead of the usual 'smooth' suture which requires knots at the angles. There are high-level level data that CS are quicker and on average need fewer additional stitches to control blood loss when KBS are used. There is additional evidence of a potential reduction in problems with healing of the uterus with KBS, it is thought that this might lead to a lower risk of problems in repeat CS as the chance of the placenta implanting into the scar might be lower. At present this evidence is based on ultrasound surveillance of scar appearance which is an indirect measure. The real risk difference will need to be explored with the examination of real world outcomes over the coming years.

There is currently no published data on KBS for uterine closure at caesarean from the UK. This cohort, although retrospective, is adequately controlled, shows excellent outcomes and signals a potential marked reduction in infectious morbidity. This potentially means a better patient experience as well as a large cost saving because of reduced re-admission rates. These data were collected as part of a service improvement project but the generalisable nature of our findings mean the finding are research and should be published.

Read the detailed description

Caesarean section (CS) is one of the most commonly performed operations worldwide and the prevalence is increasing1. There are perioperative complications including neonatal morbidity and, on the maternal side, haemorrhage, infection and organ injury2. Furthermore, there are implications for future pregnancies, the risks of which rise with each successive caesarean3. Closure of the lower segment hysterotomy at CS is most commonly affected using a 2-layer approach employing braided absorbable sutures such as Vicryl (polyglactin 910)4. Closure is with a continuous suturing technique and the tension of the closure is maintained manually until the suture is secured with knots at the angles. Knotless barbed suture (KBS) closure of the caesarean hysterotomy remains a novel technique that is not yet widely employed. These sutures, first invented in 1964, were approved by the FDA in 2004 and were first used in a clinical trial in 20075. Barbed sutures anchor themselves within the tissue, as barbs on the suture resist backward movement through the tissue. They offer even tension over the length of the hysterotomy and are cut flush with the uterus without the need for anchoring knots.

A systematic review and meta-analysis of randomised control trials (n460) on KBS compared with 'smooth' sutures at elective CS found that operative times were lower and the need for additional haemostatic sutures was lower6. There was a trend towards lower blood loss and no difference in operative morbidity. Some trials, some of which are ongoing, have examined whether there is a difference in lower segment residual myometrial thickness (RMT) after KBS and whether there is a difference in the incidence of scar niche7. These outcomes, respectively, are offered as potential proxy measures for uterine rupture risk and praevia or PAS risk. The results of these trials, as per their proxy outcomes, have been encouraging. This trial offers the first data on KBS at CS in UK practise.

Methods:

This single-centre retrospective cohort study in a tertiary care hospital in Northern England including caesarean deliveries from November 2022 to October 2024 - a 24 month period. The cohorts are women who had a Medtronic's V-loc 180 absorbable device (KBS) and women who had 2 layer vicryl (polyglactin 910) uterine closure i.e. smooth suture (SS).

Data was collected prospectively using a Microsoft Excel™ spreadsheet by the lead clinician (HS) as part of a quality improvement project and data was cross-referenced with patient records using Clevermed badgernotes ™ maternity system data records. Baseline characteristics reported are: patient age at delivery, parity, number of previous caesarean sections, BMI at booking, additional intraoperative interventions, birth-weight, indication for, and category of, caesarean, mode of anaesthesia, grade of operator and whether a consultant was present if not the primary surgeon (Table 1). The pre-specified outcome was blood loss. The pre-specified secondary outcomes were operating time, infection rates, readmission, unplanned outpatient attendance, and other complications.

Women were grouped for comparison as follows: group 1, n290 elective CS undertaken using KBS (November 2022-December 2024); group 2 - n215 Elective caesareans undertaken on a number of consultant lists using SS (May-August 2024). Group 3 - n107 Emergency caesarean deliveries using KBS (January 2023-December 2024); Group 4 - n345 emergency caesarean deliveries using SS (May-August 2024). Group 5 - n397 comprises group 1 and group 3. Group 6 - n560 comprises group 2 and group 4. The plan for data analysis was pre-specified and published prior to analysis being undertaken.

The investigators report baseline characteristics and outcomes as means (SDs), or numbers and percentages. Difference in outcome by cohort is reported as relative risk with 95% CI. Multivariate analysis was used to assess correlation for inclusion of variables in binary logistic regression for adjustment of risk. Variables felt relevant were included regardless of significance of correlation, as pre-specified - for the primary outcome, across all three comparisons, the following variables were pre-selected for inclusion in adjustment of risk: BMI, birthweight, mode of anaesthesia. For the secondary outcomes pre-specified variables for adjustment of risk across all three comparisons were as follows: for operating time; BMI, additional operative interventions, number of previous caesareans, for infection rates; BMI, category of caesarean and indication, for readmission; BMI and category of caesarean, for unplanned outpatient attendances as for readmission. There was no planed adjustment for the safety outcome of other complications. Unpaired t-tests, Chi square or Fisher's exact test were used to test significance for categorical and continuous outcomes. Analysis was carried out using IBM SPSS version 24. Alpha was taken as 0.05 for the primary outcome and 0.01 for the secondary outcomes.

02

Conditions studied

  • Caesarean Section
  • Caesarean Section; Infection

Browse trials for

Keywords

  • Knotless barbed suture
  • caesarean section
  • caesarean delivery
  • caesarean birth
03

In context

Infections

6,701 studies on the registry are indexed under Infections; 801 are open to participants now.

This study's enrollment of 957 is above the median of 240 across 2,144 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

South Tees Hospitals NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women having a caesarean section at James Cook University Hospital within the study period

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women undergoing a caesarean section at the study hospital within the data collection period for that cohort - either with or without KBS depending on the cohort.

Exclusion criteria

Exclusion Criteria:

  • Not falling within the search criteria for a comparator group
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
957 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 1 (Elective Caesareans undertaken using knotless barbed suture)

    Elective caesareans undertaken using knotless barbed sutures. This included all cases without exception on the CI's regular operating list from January 2023 (after a positive trial period which resulted in this becoming the standard for the CI). n290.

    Procedure: knotless barbed suture closure of the hysterotomy at caesarean section

  • Group 2 (Elective caesarean sections on a number of consultant lists using standard sutures SS)

    May-August 2024 all cases on the respective lists n215

    Procedure: Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)

  • Group 3 (Emergency caesarean deliveries when KBS was used for closure of the hysterotomy)

    Emergency caesarean deliveries (category 1-3 urgency - all except elective) using KBS January 2023-December 2024. n 107.

    Procedure: knotless barbed suture closure of the hysterotomy at caesarean section

  • Group 4 (Emergency caesarean deliveries employing Standard sutures for closure of the hysterotomy)

    All non-cat 4 CS using SS (May-August 2024) n 345

    Procedure: Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)

  • Group 5 (comprising all cases in group 1 and group 3)

    All the KBS caesarean deliveries n 397

    Procedure: knotless barbed suture closure of the hysterotomy at caesarean section

  • Group 6 (comprising group 2 and group 4)

    All the SS cases n560

    Procedure: Standard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)

Interventions

  • Procedureknotless barbed suture closure of the hysterotomy at caesarean section

    Use of Medtronic V-loc 180 suture (VL) for a 2 layer closure of the caesarean hysterotomy rather than the standard 2 layer closure using the 910 polyglactin suture (SS).

  • ProcedureStandard 2 layer closure of caesarean hysterotomy using 910 polyglactin suture (SS)

    Standard 2 layer closure using the 910 polyglactin suture (SS)

06

What researchers measure

Primary outcomes

  1. Post-operative infection

    Whether antibiotics were prescribed for a surgical site infective complication.

    Time frame: up to 6 weeks post-operative

Secondary outcomes

  1. operating time

    Time from knife to skin to closure of skin

    Time frame: Intraoperative

  2. Blood loss

    Estimated or measured intraoperative blood loss (estimates are used unless blood loss is thought excessive when measuring is carried out contemporaneously)

    Time frame: In theatre during the operation

  3. Readmission

    Readmission to hospital within 6 weeks post-operative for a maternal indication (not a neonatal one)

    Time frame: up to 6 weeks post-operative

  4. Re-attendance as an outpatient

    Attending hospital as an outpatient for an unscheduled review

    Time frame: up to 6 weeks post-operative

Other outcomes

  1. Operative complications

    Failure of the suture (snapping intraoperatively), organ injury (bladder, bowel, ureter), major haemorrhage (\>1.5 litre loss) or other unexpected adverse event

    Time frame: Intraoperative and up to 6 weeks post-operatively

07

Study locations

1 site
  • James Cook University Hospital
    Middlesbrough, TS43BW, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be shared via CT.gov on an excel spreadsheet without identifiable information being provided

Supporting information: Study protocol, Statistical analysis plan

Time frame: Feb 2025

Access criteria: Open access on CT.gov

Data sharing details ↗ · clinicaltrials.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Feb 2025, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 20, 2025
StartActual
Nov 1, 2022
Primary completionActual
Feb 11, 2025
CompletionActual
Feb 11, 2025
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06979687
Lead sponsor
South Tees Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Nov 1, 2022
Primary completion
Feb 11, 2025
Completion
Feb 11, 2025
Last update
May 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion